



PRESS RELEASE

Indoco's revenue grows 9% in Q3FY24

Mumbai, January 23, 2024: During the third quarter of FY 2023-24, revenues of Indoco Remedies grew by 9.2 % at Rs. 4484 mn, as against Rs. 4106 mn, same quarter last year. EBIDTA to net sales for the quarter is 14.6 % at Rs. 653 mn, compared to 15.0 % at Rs. 617 mn, same quarter last year. Profit After Tax (before exceptional item) is at Rs. 282 mn, compared to Rs. 279 mn, same quarter last year.

For the 9-month period ended Dec'23, revenues grew by 9.6 % at Rs. 13268 mn, as against Rs. 12101 mn, same period last year. EBIDTA to net sales for the period is 15.1 % at Rs. 2006 mn, compared to 18.2 % at Rs. 2207 mn, same period last year. Profit After Tax (before exceptional item) to net sales is 6.6 % at Rs. 873 mn, compared to 9.6 % at Rs. 1160 mn, same period last year.

Commenting on the results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd. said, "Our Q3 performance is primarily driven by International business - particularly US and Emerging Markets, API business and steady performance by India business".

About Indoco Remedies Limited:

Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The Company's turnover is US\$ 200 million with a human capital of over 6000 employees, including over 400 skilled scientists and Field Staff who are the strength of the organization.

The Company has 9 manufacturing facilities, 6 for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 106 million prescriptions annually from over 2,29,000 doctors belonging to various specialties. Indoco has 8 domestic marketing divisions a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritional, Cardiovascular, Anti-Diabetics, Pain Management, Gynecology etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Aloja, Glychek, Kidodent, Subital, Rexidin,

MCBM 69, Methycal, Dropizine, Noxa, Homide, Cal-Aid, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

For more details on Indoco, you may visit www.indoco.com

For Media Inquiries Please Contact:



Mr. Anuj Sonpal
Valorem Advisors
Tel: +91-22-4903-9500
Email: indoco@valoremadvisors.com